Dominic Culligan

4.9k total citations · 1 hit paper
75 papers, 2.9k citations indexed

About

Dominic Culligan is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Dominic Culligan has authored 75 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Hematology, 24 papers in Pathology and Forensic Medicine and 20 papers in Oncology. Recurrent topics in Dominic Culligan's work include Acute Myeloid Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (24 papers) and Acute Lymphoblastic Leukemia research (10 papers). Dominic Culligan is often cited by papers focused on Acute Myeloid Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (24 papers) and Acute Lymphoblastic Leukemia research (10 papers). Dominic Culligan collaborates with scholars based in United Kingdom, United States and Italy. Dominic Culligan's co-authors include Mark A. Vickers, Neil A. Marshall, Robert N. Barker, Peter Johnston, Yen‐Lin Chee, Laura Munro, Henry G. Watson, Linsey Christie, David Bowen and Sally F. Barrington and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Dominic Culligan

74 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

2015 407 citations John Radford, Tim Illidge et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dominic Culligan United Kingdom	26	1.0k	929	767	586	504	75	2.9k
Ho‐Jin Shin South Korea	22	944 0.9×	691 0.7×	655 0.9×	412 0.7×	365 0.7×	182	2.0k
Enrico Maria Pogliani Italy	26	1.4k 1.3×	580 0.6×	634 0.8×	318 0.5×	620 1.2×	96	2.7k
Edward Agura United States	22	1.6k 1.6×	1.0k 1.1×	1.1k 1.4×	858 1.5×	662 1.3×	49	2.9k
Tak Takvorian United States	27	957 0.9×	1.5k 1.7×	1.1k 1.4×	534 0.9×	899 1.8×	58	2.9k
Aspasia Stamatoullas France	34	1.4k 1.3×	1.7k 1.9×	1.3k 1.7×	393 0.7×	1.2k 2.4×	126	3.6k
J L Harousseau France	22	1.1k 1.1×	1.8k 1.9×	1.8k 2.3×	397 0.7×	815 1.6×	36	3.3k
David Westerman Australia	27	732 0.7×	1.4k 1.5×	776 1.0×	545 0.9×	1.4k 2.8×	125	2.8k
Lois Ayash United States	25	1.3k 1.3×	401 0.4×	1.3k 1.6×	451 0.8×	225 0.4×	119	2.6k
Louis F. Diehl United States	27	429 0.4×	1000 1.1×	630 0.8×	596 1.0×	1.0k 2.1×	85	2.3k
Réda Bouabdallah France	28	1.5k 1.4×	1.9k 2.1×	2.0k 2.6×	577 1.0×	913 1.8×	101	4.0k

Countries citing papers authored by Dominic Culligan

Since Specialization

Citations

This map shows the geographic impact of Dominic Culligan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dominic Culligan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dominic Culligan more than expected).

Fields of papers citing papers by Dominic Culligan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dominic Culligan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dominic Culligan. The network helps show where Dominic Culligan may publish in the future.

Co-authorship network of co-authors of Dominic Culligan

This figure shows the co-authorship network connecting the top 25 collaborators of Dominic Culligan. A scholar is included among the top collaborators of Dominic Culligan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dominic Culligan. Dominic Culligan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Killick, Sally, Wendy Ingram, Dominic Culligan, et al.. (2021). British Society for Haematology guidelines for the management of adult myelodysplastic syndromes. British Journal of Haematology. 194(2). 267–281. 14 indexed citations

Killick, Sally, Daniel H. Wiseman, Lynn Quek, et al.. (2021). British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. British Journal of Haematology. 194(2). 282–293. 5 indexed citations

Dignan, Fiona L., Angela Hamblin, Jungwha Lee, et al.. (2020). Survivorship care for allogeneic transplant patients in the UK NHS: changes centre practice, impact of health service policy and JACIE accreditation over 5 years. Bone Marrow Transplantation. 56(3). 673–678. 7 indexed citations

Radford, John, Tim Illidge, Nicholas Counsell, et al.. (2015). Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. New England Journal of Medicine. 372(17). 1598–1607. 407 indexed citations breakdown →

Follows, George, Kirit M. Ardeshna, Sally F. Barrington, et al.. (2014). Guidelines for the first line management of classical Hodgkin lymphoma. British Journal of Haematology. 166(1). 34–49. 60 indexed citations

Taylor, Gordon, et al.. (2013). Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot–Leyden crystals. International Journal of Hematology. 98(3). 267–268. 8 indexed citations

Dennis, Michael, Dominic Culligan, Dimitris Karamitros, et al.. (2013). Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities. Leukemia Research Reports. 2(2). 70–74. 7 indexed citations

Proctor, Stephen J., Jennifer Wilkinson, Gail Jones, et al.. (2012). Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 119(25). 6005–6015. 58 indexed citations

Burnett, Alan K., Nigel H. Russell, Dominic Culligan, et al.. (2012). The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. British Journal of Haematology. 158(4). 519–522. 42 indexed citations

10.

Barbour, Robert H., Dominic Culligan, Graham Macdonald, et al.. (2012). Factors affecting decision making about fertility preservation after cancer diagnosis: a qualitative study. BJOG An International Journal of Obstetrics & Gynaecology. 119(9). 1049–1057. 109 indexed citations

11.

Cezard, Timothée, et al.. (2012). Exome Sequencing and Linkage Analysis Implicates Two Candidate Genes On Chromosome 3p in Familial Hodgkin Lymphoma. Blood. 120(21). 53–53. 2 indexed citations

12.

Crowther, Mark, Alison Avenell, & Dominic Culligan. (2010). Being underweight may reduce your ability to mobilise peripheral blood stem cells. Transfusion and Apheresis Science. 43(3). 365–367. 3 indexed citations

13.

Proctor, S.J., Anne Lennard, Graham Jackson, et al.. (2009). The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control. Annals of Oncology. 21(2). 426–428. 7 indexed citations

14.

Crowther, Mark, Alison Avenell, & Dominic Culligan. (2009). Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. Bone Marrow Transplantation. 44(7). 413–425. 47 indexed citations

15.

Johnston, Peter, et al.. (2006). A case of hepatosplenic γ–δ T‐cell lymphoma with a transient response to Fludarabine and Alemtuzumab. European Journal Of Haematology. 76(6). 531–534. 52 indexed citations

16.

Rao, Sheela, David Watkins, David Cunningham, et al.. (2004). Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Annals of Oncology. 15(9). 1413–1418. 37 indexed citations

17.

Knapper, Steven, Alan K. Burnett, Jonathan Kell, et al.. (2004). A Phase II Trial of the FLT3 Inhibitor CEP701 as First Line Treatment for Older Patients with Acute Myeloid Leukaemia Not Considered Fit for Intensive Chemotherapy.. Blood. 104(11). 864–864. 4 indexed citations

18.

Guidez, Fabien, Lucia Altucci, Ke Xu, et al.. (2001). Rexinoid therapy bypasses the differentiation block associated with acute promyelocytic leukemia harboring the PLZF/RAR alpha rearrangement.. Blood. 98(11). 3 indexed citations

19.

Chee, Yen‐Lin, Dominic Culligan, & Henry G. Watson. (2001). Inferior vena cava malformation as a risk factor for deep venous thrombosis in the young. British Journal of Haematology. 114(4). 878–880. 169 indexed citations

20.

Robbie, L. A., Susan A. Berry, Nuala A. Booth, et al.. (2000). Myeloid leukaemic cells can lyse fibrin directly. British Journal of Haematology. 111(2). 524–529. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact